Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

NCT00053248 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: arsenic trioxide
DRUG: imatinib mesylate

Sponsor

OHSU Knight Cancer Institute

Collaborators

[object Object]